Evaluation of Testosterone therapy in Heart Failure
- Conditions
- Congestive Heart Failure.I50.0
- Registration Number
- IRCT2013070113828N1
- Lead Sponsor
- Islamic Azad University, Najafabad Branch
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 50
Inclusion criteria were: 1 -Male Gender and age 50-80 with 2 - Heart Failure approved by Echocardiography and 6MWT test 3 -Having clinically stable heart condition in the last three months and not hospitalized for heart failure problems 4 - Classes II and III are classified as being in NYHA 5 - Ejection fraction(EF) less than 40 percent 6 - No signs of unstable angina and myocardial infarction in recent months 7 - Absence of severe liver and pulmonary disease 8 -Absence of uncontrolled hypertension 9 - No erytrocytosis (hematocrit = 50%) 10 - No history of breast and prostate cancer and no history of prostate nodules, 11 - Absence of lower urinary tract symptoms and severe BPH disease and high levels of PSA 12 -Consent patients into the study.
Exclusion criteria were: 1 - Cancel patient continued therapy 2 -Patient not continue more than a month after the injection,3 - oversensitivity to drug and important side effects - 4 patients died during the study.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of Cardiovascular parameter like Ejection Fraction/Diastolic function and Left Ventricular Dimentions at the end of Systole and Diastole. Timepoint: Before intervention and also as endpoint after 12 weeks. Method of measurement: Echocardiography.;Quality Of Llife. Timepoint: Before intervention and also at endpoint after 12 weeks. Method of measurement: Quality Of Llife Questionnaire.;Depression status. Timepoint: Before intervention and also at endpoint after 12 weeks. Method of measurement: Beck Questionnaire.;Changes in body weight. Timepoint: Baseline and also at the end of each month. Method of measurement: Weight scale.;Muscle strength. Timepoint: Baseline and also at the end of each month. Method of measurement: Hand Dynamometer.;6-Minute Walk Distance (6MWD). Timepoint: Baseline and also at the end of each month. Method of measurement: Measurment of distance that patients had walked within 6 minute in hospital coridour.
- Secondary Outcome Measures
Name Time Method PSA measure. Timepoint: Before intervention and also as endpoint after 12 weeks. Method of measurement: ELISA Method.